Ameritas Investment Partners’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Ameritas Investment Partners’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-367	Closed	-$4K	–	3270
2022 Q1	$4K	Hold	367	–	–	﹤0.01%	3015
2021 Q4	$12K	Hold	367	–	–	﹤0.01%	2850
2021 Q3	$16K	Hold	367	–	–	﹤0.01%	2813
2021 Q2	$20K	Hold	367	–	–	﹤0.01%	2745
2021 Q1	$27K	Hold	367	–	–	﹤0.01%	2437
2020 Q4	$40K	Hold	367	–	–	﹤0.01%	2115
2020 Q3	$32K	Hold	367	–	–	﹤0.01%	2127
2020 Q2	$39K	Buy	367 +107	+41%	+$9.6K	﹤0.01%	1986
2020 Q1	$15K	Hold	260	–	–	﹤0.01%	2346
2019 Q4	$18K	Hold	260	–	–	﹤0.01%	2469
2019 Q3	$27K	Hold	260	–	–	﹤0.01%	2238
2019 Q2	$24K	Hold	260	–	–	﹤0.01%	2351
2019 Q1	$24K	Hold	260	–	–	﹤0.01%	2295
2018 Q4	$14K	Hold	260	–	–	﹤0.01%	2528
2018 Q3	$31K	Hold	260	–	–	﹤0.01%	2274
2018 Q2	$27K	Buy	260 +150	+136%	+$18.6K	﹤0.01%	2342
2018 Q1	$14K	Hold	110	–	–	﹤0.01%	2606
2017 Q4	$11K	Hold	110	–	–	﹤0.01%	2721
2017 Q3	$21K	Hold	110	–	–	﹤0.01%	2399
2017 Q2	$18K	Buy	110 +73	+197%	+$11.5K	﹤0.01%	2533
2017 Q1	$6K	Buy	+37	New	+$4.51K	﹤0.01%	2820

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ameritas Investment Partners's SYRS Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2022, closing a stake of 367 shares — an estimated $4K sold.

Ameritas Investment Partners first reported a position in SYRS in Q1 2017 and held it in 21 quarters. The position peaked at $40K in Q4 2020. 67 funds tracked by Wall St. Rank hold SYRS as of Q2 2022.

Ameritas Investment Partners reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Ameritas Investment Partners sold 367 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $4K.
Ameritas Investment Partners first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2017 and held it in 21 quarters.
Ameritas Investment Partners's Syros Pharmaceuticals, Inc. Common Stock position peaked at $40K in Q4 2020.
67 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.